Method of treating ulcerative colitis and Crohn's disease using IL-17 receptor proteins
View Patent ↗Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor IL-1 and/or TNF.
1. A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein is selected from the group consisting of:
(a) a protein comprising amino acids 28 through 320 of SEQ ID NO:4;
(b) a protein comprising amino acid sequence that is at least 80% identical to the amino acid sequence of (a) and binds IL-17; and
(c) a fragment of (a) that binds IL-17.
2. The method according to claim 1 , wherein the soluble IL-17R protein further comprises an Fc domain.
3. The method according to claim 1 , wherein the soluble IL-17R protein further comprises an oligomerizing domain.
4. A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises amino acids 28 through 320 of SEQ ID NO:4.
5. A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a protein having an amino acid sequence that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:4 and binds IL-17.
6. A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a fragment of amino acids 28 through 320 of SEQ ID NO:4 that binds IL-17.
7. A method of treating a mammal afflicted with Chrohn's disease, the method comprising administering to said mammal an effect amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein is selected from the group consisting of:
(a) a protein comprising amino acids 28 through 320 of SEQ ID NO:4;
(b) a protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of (a) and binds IL-17; and
(c) a fragment of (a) that binds IL-17.
8. The method according to claim 7 , wherein the soluble IL-17R protein further comprises an Fc domain.
9. The method according to claim 7 , wherein the soluble IL-17R protein further comprises an oligomerizing domain.
10. A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17R Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises amino acids 28 through 320 of SEQ ID NO:4.
11. A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17R Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a protein having an amino acid sequence that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:4 and binds IL-17.
12. A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17R Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a fragment of amino acids 25 through 320 of SEQ ID NO:4 that binds IL-17.